1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: Characteristics of patients with absent bone marrow edema (no BME) in treated osteoporotic vertebral compression fractures (VCF) (group I) and patients with full BME (full BME) in treated VCF (group II) prior to percutaneous vertebroplasty (PV)
Group I, No BME Group II, Full BME P value
Total no. of study patients 14 31 
Mean age, y (range) 71 (47–88) 75 (51–88) .5
    Median 69 70 
Women (%) 12 (86) 27 (87) .9
No. of VCF treated by PV 22 38 .01
Patients with multiple treated VCF (%) 7 (50) 7 (23) .1
Mean age treated VCF, (no) (range) 8.3 (3–36) 4.7 (2–24) .07
    Median 5.5 3.0 
Extent bone marrow edema in treated VCF 
    Absent (0%) 22 
    Full (100%) 38 
Shape of treated VCF 
    Wedge (%) 17 (77) 28 (74) .7
    Biconcave (%) 5 (23) 9 (24) 
    Crush (%) 1 (2) 
Grade of treated VCF 
    Mild (%) 14 (64) 8 (21) <.01
    Moderate (%) 8 (36) 14 (37) 
    Severe (%) 16 (42) 
Mean injected cement volume, mm³ (range) 3.5 (1.2–5.5) 2.7 (1.0–4.5) <.01
    Median 4.0 2.5 
Mean initial VAS (range) 8.6 (7–10) 8.6 (6–10) .9
    Median 8.0 9.0 
Initial analgesic use 
    No (%) 14 0 .2
    Paracetamol (%) 14 16 
    NSAID (%) 29 29 
    Opiate derivative (%) 43 55 
Note:—VAS indicates visual analogue score; NSAID, nonsteroidal anti-inflammatory drug.